Recent Recurrent Melanoma News

Yervoy® May be Beneficial in Uveal Melanoma (December 8, 2014)

The first trial of the immunomodulator Yervoy® (ipilimumab) conducted in patients with uveal melanoma appears promising in according to the results of a small clinical trial presented at the recent Society... Continue Reading

Injecting of PV-10 is Promising Treatment of Melanoma Lesions (November 25, 2014)

The results of an international clinical trial evaluating the use of intralesional rose bengal (PV-10), injected in 80 patients with refractory cutaneous or subcutaneous metastatic melanoma were recently... Continue Reading

New Information Helps Understanding Immunotherapy’s Successes—And Its Failures (November 24, 2014)

(OMNI- CancerConnect) A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some... Continue Reading

Nivolumab Superior to Chemotherapy in First Phase III Trial as Initial Treatment in Advanced Melanoma (November 20, 2014)

The immunotherapy drug nivolumab produces significantly better overall survival than chemotherapy as initial treatment in advanced melanoma, according to findings from its first Phase III study in previously... Continue Reading

Thin Melanomas Responsible for Many Melanoma Related Deaths (November 19, 2014)

According to a new study published in The Journal of Investigative Dermatology, more people are dying from melanomas thinner than a dime than from thicker skin lesions, which have long been thought to... Continue Reading

Progress in the Treatment of Advanced Melanoma and Other Skin Cancers (November 14, 2014)

By one estimate, over the past three decades more people in the United States have had skin cancer than all other cancers combined.1 According to the American Cancer Society, 3.5 million cases of basal... Continue Reading

Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma (November 12, 2014)

(CancerConnect) Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously... Continue Reading

Targeted Therapy Nivolumab Outperforms Chemotherapy in Advanced Melanoma (October 13, 2014)

Nivolumab appears to be more active and safer than chemotherapy in patients with advanced melanoma who have received previous treatment. These findings were presented at the 2014 European Society for Medical... Continue Reading

COMBI-v BRAF/MEK Inhibitor Combination Trial Impressive in Melanoma (October 8, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the... Continue Reading

BRAF/MEK Inhibitor Combination Impressive in Melanoma Trials (October 2, 2014)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology Meeting this week. Of the... Continue Reading

Next Page »